Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377336 | 0.93 | SLC6A4 (0.38) | HTR2AHTR2CHTR2BHSD11B1SLC6A4 | |
| SCHEMBL8481056 | 0.83 | HSD11B1 (0.39) | HSD11B1SLC6A4CA1CA2KDM4C | |
| SCHEMBL3519977 | 0.81 | ALDH1A1 (0.34) | HSD11B1HPGD | |
| SCHEMBL3518657 | 0.76 | MEN1 (0.37) | HTT | |
| SCHEMBL8382519 | 0.74 | HSD11B1 (0.33) | HSD11B1HPGD | |
| SCHEMBL6994885 | 0.73 | IDO1 (0.50) | IDO1KDM4C | |
| SCHEMBL18153009 | 0.73 | KDM4C (0.34) | KDM4C | |
| SCHEMBL15779251 | 0.73 | ESR2 (0.38) | — | |
| SCHEMBL10512796 | 0.71 | KEAP1 (0.39) | KDM4C | |
| SCHEMBL26419673 | 0.70 | KDM4C (0.39) | SLC6A4IDO1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1959959-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067511-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | PROKR2, PROKR1, NTSR2 | HTR2A 31/4885HTR2C 40/4885HTR2B 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.